On July 13, 2026, eligible early Alzheimer's patients gained a second way to start Leqembi. Leqembi is lecanemab, an anti-amyloid drug that clears amyloid-beta plaques linked to Alzheimer's, and patients can now choose home shots or clinic IV infusions. Eisai and Biogen said in the official approval announcement that weekly shots can start treatment from day one. Eisai also reported equivalent drug exposure with shots and IV, supporting similar amyloid removal and clinical benefit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
Table of Contents
- What changed for starting treatment?
- Who can consider treatment?
- How do home shots compare with IV infusions?
- Why does home treatment still need clinic visits?
- What can you ask a specialist?
What changed for starting treatment?
The new initiation option is LEQEMBI IQLIK, a subcutaneous form of lecanemab for early Alzheimer's. The approved home start is 500 mg once weekly as two back-to-back 250 mg autoinjector shots, each given in about 15 seconds, according to Eisai and Biogen.
After 18 months of IV or subcutaneous treatment, patients may move to 360 mg weekly by shot for maintenance. Patients may also switch between IV and subcutaneous routes during treatment, according to Eisai and Biogen.
Who can consider treatment?
FDA prescribing information states in the current Leqembi label that treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Those patients must have confirmed amyloid-beta pathology before starting treatment.
The FDA package insert also carries a boxed warning for ARIA-edema and ARIA-hemosiderin deposition. ARIA means amyloid-related imaging abnormalities, with edema as swelling and hemosiderin deposition linked to small bleeds. Risk for symptomatic and severe ARIA is higher in ApoE e4 homozygotes, people with two copies of that gene variant, so ApoE e4 testing should come before treatment.
How do home shots compare with IV infusions?
The main difference is place, time, and dosing method. Home treatment uses a fixed weekly shot.
Clinic treatment uses a weight-based IV dose on a two-week cycle. The original IV start requires dilution and an hour-long infusion, according to FDA prescribing information. The shot removes travel for each dose, but it does not remove the need for clinic exams, brain scans, and safety checks.
- Home start: 500 mg weekly as two 15-second shots
- Clinic start: 10 mg/kg IV over about one hour every two weeks for 18 months
- Home maintenance: 360 mg weekly by shot after 18 months
- IV maintenance: IV every four weeks after 18 months
- Switch: patients may change routes during treatment
Why does home treatment still need clinic visits?
The FDA label requires a recent baseline brain MRI plus follow-up MRIs before the 3rd, 5th, 7th, and 14th infusions to look for ARIA, as stated in the 2025 FDA prescribing information. Home shots do not replace those imaging visits.
Eisai and Biogen reported generally similar safety between weekly shots and IV, except for mostly localized injection reactions with shots. Because ARIA can occur with either route, symptoms that need fast care include headache, confusion, dizziness, vision change, trouble walking, or sudden weakness.
What can you ask a specialist?
Use the visit to match the two routes to your health, schedule, and support at home. A specialist can explain eligibility, gene risk, scan timing, and who teaches the shots. Bring your recent MRI dates, ApoE e4 result, full drug list, and names of people who can help with weekly shots.
- Do my symptoms and amyloid test results meet the early-stage criteria?
- What does my ApoE e4 result mean for my ARIA risk?
- How will my MRI dates be set if I start with home shots?
- When could I enter maintenance, and could I switch routes later?
- Who will train us on the autoinjectors and watch for side effects?
You Might Also Like
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- The Long-Term Care Data Cooperative and Dementia Research in 2026: Questions Spouses and Partners Can Ask About the Research





